|
CGM Dynamic Index for Predicting Prediabetes in Cystic Fibrosis
RECRUITINGN/ASponsored by Indiana University
Actively Recruiting
PhaseN/A
SponsorIndiana University
Started2025-06-15
Est. completion2026-06-30
Eligibility
Age12 Years – 55 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT06642610
Summary
The primary objective of this pilot study is to develop a CGM-based model to predict the progression from prediabetes to diabetes in individuals with cystic fibrosis.
Eligibility
Age: 12 Years – 55 YearsHealthy volunteers accepted
Inclusion Criteria: * CF individuals aged 12-55 years. * CF without diabetes or with prediabetes (as defined by OGTT and HbA1c). * Willing to use a continuous glucose monitoring system with compatible smart phone for glucose data collection. A person with CFRD and already using CGM, we will just collect their personal CGM data, and they are not required to have OGTT or HbA1c visit. Exclusion Criteria: * Pregnancy. * History of transplant. * Use of immunosuppressant drugs. * Use of oral steroids or any medication known to interfere with glucose. * Allergy to adhesives. * Individuals with severe concurrent medical conditions that could confound glucose monitoring data (e.g., terminal illness, major organ failure). * Conditions that may make unsafe for participants to do study or impair or confound the study at the discretion of the investigator
Conditions4
Cystic Fibrosis (CF)Cystic Fibrosis-related DiabetesDiabetesPreDiabetes
Locations1 site
Indiana University Health, University Hospital
Indianapolis, Indiana, 46202
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorIndiana University
Started2025-06-15
Est. completion2026-06-30
Eligibility
Age12 Years – 55 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →
NCT06642610